Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
14
02
2019
accepted:
15
07
2019
revised:
03
07
2019
pubmed:
20
9
2019
medline:
22
6
2021
entrez:
20
9
2019
Statut:
ppublish
Résumé
Plerixafor plus granulocyte-colony stimulating factor (G-CSF) enhances the mobilization of hematopoietic stem cells (HSCs) for collection and subsequent autologous hematopoietic stem cell transplantation (HSCT) in patients with multiple myeloma (MM). This international, multicenter, noninterventional registry study (NCT01362972), evaluated long-term outcomes for MM patients who received plerixafor versus other mobilization regimens. The comparisons were: G-CSF + plerixafor (G-CSF + P) versus G-CSF-; G-CSF + P versus G-CSF + chemotherapy (G-CSF + C); and G-CSF + P + C versus G-CSF + C. Propensity score matching was used to balance groups. Primary outcome measures were progression free survival (PFS), overall survival (OS), and cumulative incidence of relapse (CIR) after transplantation. After propensity matching, 77 versus 41 patients in the G-CSF + P versus G-CSF cohorts, 129 versus 129 in the G-CSF + P versus G-CSF + C cohorts, and 117 versus 117 in the G-CSF + P + C versus G-CSF + C cohorts were matched, respectively. Propensity score matching resulted in a smaller sample size and imbalances were not completely overcome. For both PFS and OS, the upper limits of the hazard ratio 95% confidence intervals exceeded prespecified boundaries; noninferiority was not demonstrated. CIR rates were higher in the plerixafor cohorts. G-CSF + P remains an option for the mobilization of HSCs in poor mobilizers with MM with no substantial differences in PFS, OS, and CIR in comparison with other regimens.
Identifiants
pubmed: 31534192
doi: 10.1038/s41409-019-0676-0
pii: 10.1038/s41409-019-0676-0
pmc: PMC6995780
doi:
Substances chimiques
Benzylamines
0
Cyclams
0
Heterocyclic Compounds
0
plerixafor
S915P5499N
Banques de données
ClinicalTrials.gov
['NCT01362972']
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
356-366Références
DiPersio JF, Uy GL, Yasothan U, Kirkpatrick P. Plerixafor. Nat Rev Drug Discov. 2009;8:105–6. https://doi.org/10.1038/nrd2819 .
doi: 10.1038/nrd2819
pubmed: 19180104
Nervi B, Link DC, DiPersio JF. Cytokines and hematopoietic stem cell mobilization. J Cell Biochem. 2006;99:690–705. https://doi.org/10.1002/jcb.21043 .
doi: 10.1002/jcb.21043
pubmed: 16888804
Fruehauf S, Seeger T. New strategies for mobilization of hematopoietic stem cells. Future Oncol. 2005;1:375–83. https://doi.org/10.1517/14796694.1.3.375 .
doi: 10.1517/14796694.1.3.375
pubmed: 16556011
Lapidot T, Dar A, Kollet O. How do stem cells find their way home? Blood. 2005;106:1901–10. https://doi.org/10.1182/blood-2005-04-1417 .
doi: 10.1182/blood-2005-04-1417
pubmed: 15890683
Pirracchio R, Resche-Rigon M, Chevret S. Evaluation of the propensity score methods for estimating marginal odds ratios in case of small sample size. BMC Med Res Methodol. 2012;12:70 https://doi.org/10.1186/1471-2288-12-70 .
doi: 10.1186/1471-2288-12-70
pubmed: 22646911
pmcid: 3511219
Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958;53:457–81.
doi: 10.1080/01621459.1958.10501452
Brioli A, Perrone G, Patriarca F, Pezzi A, Nobile F, Ballerini F, et al. Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation. Bone Marrow Transpl. 2015;50:673–8. https://doi.org/10.1038/bmt.2014.322 .
doi: 10.1038/bmt.2014.322
Shah N, Callander N, Ganguly S, Gul Z, Hamadani M, Costa L, et al. Hematopoietic stem cell transplantation for multiple myeloma: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transpl. 2015;21:1155–66. https://doi.org/10.1016/j.bbmt.2015.03.002 .
doi: 10.1016/j.bbmt.2015.03.002
Lee KH, Jung SK, Kim SJ, Jang JH, Kim K, Kim WS, et al. Incidence and risk factors of poor mobilization in adult autologous peripheral blood stem cell transplantation: a single-centre experience. Vox Sang. 2014;107:407–15. https://doi.org/10.1111/vox.12183 .
doi: 10.1111/vox.12183
pubmed: 25130876
Sancho JM, Morgades M, Grifols JR, Junca J, Guardia R, Vives S, et al. Predictive factors for poor peripheral blood stem cell mobilization and peak CD34(+) cell count to guide pre-emptive or immediate rescue mobilization. Cytotherapy. 2012;14:823–9. https://doi.org/10.3109/14653249.2012.681042 .
doi: 10.3109/14653249.2012.681042
pubmed: 22540329
Wuchter P, Ran D, Bruckner T, Schmitt T, Witzens-Harig M, Neben K, et al. Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transpl. 2010;16:490–9. https://doi.org/10.1016/j.bbmt.2009.11.012 .
doi: 10.1016/j.bbmt.2009.11.012
Cook G, Williams C, Brown JM, Cairns DA, Cavenagh J, Snowden JA, et al. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:874–85. https://doi.org/10.1016/S1470-2045(14)70245-1 .
doi: 10.1016/S1470-2045(14)70245-1
pubmed: 24948586
Giralt S, Garderet L, Durie B, Cook G, Gahrton G, Bruno B, et al. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on salvage hematopoietic cell transplantation in patients with relapsed multiple myeloma. Biol Blood Marrow Transpl. 2015;21:2039–51. https://doi.org/10.1016/j.bbmt.2015.09.016 .
doi: 10.1016/j.bbmt.2015.09.016
Maybury B, Cook G, Pratt G, Yong K, Ramasamy K. Augmenting autologous stem cell transplantation to improve outcomes in myeloma. Biol Blood Marrow Transpl. 2016;22:1926–37. https://doi.org/10.1016/j.bbmt.2016.06.004 .
doi: 10.1016/j.bbmt.2016.06.004
Pratt G, Morris TC. Review of the NICE guidelines for multiple myeloma. Int J Lab Hematol. 2017;39:3–13. https://doi.org/10.1111/ijlh.12581 .
doi: 10.1111/ijlh.12581
pubmed: 27997752
Kim JS, Yoon DH, Park S, Yoon SS, Cho SG, Min CK, et al. Prognostic factors for re-mobilization using plerixafor and granulocyte colony-stimulating factor (G-CSF) in patients with malignant lymphoma or multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy: the Korean multicenter retrospective study. Ann Hematol. 2016;95:603–11. https://doi.org/10.1007/s00277-016-2589-y .
doi: 10.1007/s00277-016-2589-y
pubmed: 26754633
Sheppard D, Bredeson C, Huebsch L, Allan D, Tay J. A plerixafor-based strategy allows adequate hematopoietic stem cell collection in poor mobilizers: results from the Canadian Special Access Program. Bone Marrow Transpl. 2014;49:751–5. https://doi.org/10.1038/bmt.2014.33 .
doi: 10.1038/bmt.2014.33
Spoerl S, Peter R, Wascher D, Gotze K, Verbeek M, Peschel C, et al. Patients’ outcome after rescue plerixafor administration for autologous stem cell mobilization: a single-center retrospective analysis. Transfusion. 2017;57:115–21. https://doi.org/10.1111/trf.13883 .
doi: 10.1111/trf.13883
pubmed: 27859332
Micallef IN, Stiff PJ, Nademanee AP, Maziarz RT, Horwitz ME, Stadtmauer EA, et al. Plerixafor plus granulocyte colony-stimulating factor for patients with non-hodgkin lymphoma and multiple myeloma: long-term follow-up report. Biol Blood Marrow Transpl. 2018;24:1187–95. https://doi.org/10.1016/j.bbmt.2018.01.039 .
doi: 10.1016/j.bbmt.2018.01.039
Nahi H, Celanovic M, Liu Q, Lund J, Peceliunas V. A pilot, exploratory, randomized, phase ii safety study evaluating tumor cell mobilization and apheresis product contamination in patients treated with granulocyte colony-stimulating factor alone or plus plerixafor. Biol Blood Marrow Transpl. 2019;25:34–40. https://doi.org/10.1016/j.bbmt.2018.08.020 .
doi: 10.1016/j.bbmt.2018.08.020
Chang H, Qi XY, Samiee S, Yi QL, Chen C, Trudel S, et al. Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation. Bone Marrow Transpl. 2005;36:793–6. https://doi.org/10.1038/sj.bmt.1705131 .
doi: 10.1038/sj.bmt.1705131
Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood. 2007;109:3489–95. https://doi.org/10.1182/blood-2006-08-040410 .
doi: 10.1182/blood-2006-08-040410
pubmed: 17209057
Shaughnessy JD Jr., Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109:2276–84. https://doi.org/10.1182/blood-2006-07-038430 .
doi: 10.1182/blood-2006-07-038430
pubmed: 17105813
Garrido MM, Kelley AS, Paris J, Roza K, Meier DE, Morrison RS, et al. Methods for constructing and assessing propensity scores. Health Serv Res. 2014;49:1701–20. https://doi.org/10.1111/1475-6773.12182 .
doi: 10.1111/1475-6773.12182
pubmed: 24779867
pmcid: 4213057
Costa LJ, Abbas J, Hogan KR, Kramer C, McDonald K, Butcher CD, et al. Growth factor plus preemptive (‘just-in-time’) plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure. Bone Marrow Transpl. 2012;47:1403–8. https://doi.org/10.1038/bmt.2012.60 .
doi: 10.1038/bmt.2012.60
Wehr VH, Corneau JM. Efficacy and cost analysis of a plerixafor protocol for peripheral blood stem-cell mobilization in patients with multiple myeloma or non-hodgkin lymphoma. J Hematol Oncol Pharm. 2016;6:139–43.
Micallef IN, Sinha S, Gastineau DA, Wolf R, Inwards DJ, Gertz MA, et al. Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization. Biol Blood Marrow Transpl. 2013;19:87–93. https://doi.org/10.1016/j.bbmt.2012.08.010 .
doi: 10.1016/j.bbmt.2012.08.010
Douglas KW, Gilleece M, Hayden P, Hunter H, Johnson PRE, Kallmeyer C, et al. UK consensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high-dose chemoradiotherapy for patients with malignancy. J Clin Apher. 2018;33:46–59. https://doi.org/10.1002/jca.21563 .
doi: 10.1002/jca.21563
pubmed: 28631842
Duong HK, Savani BN, Copelan E, Devine S, Costa LJ, Wingard JR, et al. Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transpl. 2014;20:1262–73. https://doi.org/10.1016/j.bbmt.2014.05.003 .
doi: 10.1016/j.bbmt.2014.05.003
Moreb JS, Byrne M, Shugarman I, Zou F, Xiong S, May WS, et al. Poor peripheral blood stem cell mobilization affects long-term outcomes in multiple myeloma patients undergoing autologous stem cell transplantation. J Clin Apher. 2018;33:29–37. https://doi.org/10.1002/jca.21556 .
doi: 10.1002/jca.21556
pubmed: 28556233